NCT00668525

Escitalopram in Adult Patients With Major Depressive Disorder

A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 877 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Escitalopram	Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
DRUG	Placebo	Placebo, oral administration, once daily dosing for 8 weeks
DRUG	Escitalopram	Escitalopram high dose, oral administration, once daily dosing for 8 weeks

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-02-01
• First posted: 2008-04-29
• Last updated: 2010-05-11
• Results posted: 2010-05-06

Locations

45 sites across 1 country: United States